scispace - formally typeset
H

Howard N. Hodis

Researcher at University of Southern California

Publications -  318
Citations -  24700

Howard N. Hodis is an academic researcher from University of Southern California. The author has contributed to research in topics: Menopause & Intima-media thickness. The author has an hindex of 74, co-authored 297 publications receiving 22233 citations. Previous affiliations of Howard N. Hodis include Oklahoma Medical Research Foundation.

Papers
More filters
Journal ArticleDOI

Carotid Artery Stiffness and Cognitive Decline Among Women With or at Risk for HIV Infection.

TL;DR: Higher carotid stiffness was independently associated with faster decline in executive functioning, information processing, and psychomotor speed even in mostly middle-aged minority women and regardless of HIV serostatus, highlighting the need for cardiovascular risk factor modification in this at-risk population.
Journal ArticleDOI

Antiatherosclerosis interventions in women.

TL;DR: Hormone replacement therapy for the reduction of atherosclerosis progression and cardiovascular events has become complicated because of conflicting outcomes from recent surrogate end point studies and secondary prevention randomized clinical trials.
Journal ArticleDOI

In vivo hypertensive arterial wall uptake of radiolabeled liposomes.

TL;DR: It is concluded that neutral small unilamellar liposomes can be used to carry agents into the arterial wall in vivo in the study of hypertensive vascular disease and could be especially useful for the delivery of pharmacologically or biologically active agents that would otherwise be inactivated within the circulation or are impermeable to the arterIAL wall.
Journal ArticleDOI

Risk factor assessment, treatment strategy and prevention of coronary artery disease: the need for a more rational approach.

TL;DR: There now exists a large body of evidence which indicates that low-density-lipoprotein cholesterol (LDL-C) lowering can stabilize and regress coronary artery disease (CAD) and there remains little doubt that aggressive LDL-C lowering with lipid-lowering drugs is clinically indicated.